Deals

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC
AstraZenecaDizal Pharmaceutical

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA: 688192) announced that it has received a US$600 million upfront payment from AstraZeneca plc (NYSE: AZN), stemming from the global exclusive licensing agreement for…

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Xtalpi Invests in Alternative Bio for Cancer and Inflammation Drugs
AIAlternative Bio

Xtalpi Invests in Alternative Bio for Cancer and Inflammation Drugs

VectorBuilder and Eureka Bio Form Alliance to Advance CGT Solutions Globally
Cell-therapyEureka Biotechnology

VectorBuilder and Eureka Bio Form Alliance to Advance CGT Solutions Globally

Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal
AbbVieAiolos Bio

Bain Capital to Acquire Tanabe Pharma in JPY 510 Billion Deal

Henlius Biotech Licenses HLX15 to Dr. Reddy's for US and European Markets
BiosimilarsBOM: 500124

Henlius Biotech Licenses HLX15 to Dr. Reddy’s for US and European Markets

Show More